Related Experiment Video
Updated: Jul 16, 2026

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
Published on: October 10, 2025
Community experience with bortezomib in patients with multiple myeloma
Adedayo A Onitilo1, Jessica Engel, Bankole Olatosi
1Department of Hematology/Oncology, Marshfield Clinic-Weston Center, Weston, WI 54476, USA. onitilo.adedayo@marshfieldclinic.org
Abstract:
Community practice experience allows a nonselective care of patient using information derived from a more controlled clinical trial environment. We present our community experience with multiple myeloma patients with advanced age, long disease duration since diagnosis, advanced stage, multiple prior therapies including stem cell transplantation, co-morbidities, and other poor prognostic features, such as low albumin, high B-2 microglobulin, renal failure, and the presence of poor risk chromosomal abnormalities. Our response rates are comparable to those from clinical trials. Bortezomib is well tolerated in this population of multiple myeloma patients with the exception of infection adverse events that are generally mild grade 1-2.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
